BranchLab has built a privacy-first, AI-native platform that replaces fragmented, offline commercialization workflows for pharmaceutical companies by putting audience identification, activation, and optimization into near real-time use. Its transformer-based architecture allows models to be trained within customer-controlled environments while deploying only non-sensitive demographic and media-side signals. BranchLab says leading pharmaceutical companies use the platform and that it has driven an average increase of nearly 70% in marketing efficacy across therapeutic areas. The company is based in Boulder, Colo., and has raised a total of $35 million after closing a $26 million Series A. BranchLab plans to use the new funding to expand enterprise deployments, deepen integrations across the healthcare and media ecosystem, and further develop its unified AI commercialization platform.

Total raised

$26M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026